Replimune Group Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Replimune Group sono diminuiti a un tasso annuo medio di -31.4%, mentre il settore Biotechs ha visto gli utili crescere a un tasso annuo di 7.7%.

Informazioni chiave

-31.4%

Tasso di crescita degli utili

-19.1%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	-14.6%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-55.8%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Ripartizione dei ricavi e delle spese

Come Replimune Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

DB:7R8 Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-213	61	169
30 Jun 24	-220	60	175
31 Mar 24	-216	61	172
31 Dec 23	-210	59	167
30 Sep 23	-199	57	155
30 Jun 23	-182	55	134
31 Mar 23	-174	51	123
31 Dec 22	-157	46	107
30 Sep 22	-147	45	96
30 Jun 22	-133	42	87
31 Mar 22	-118	39	76
31 Dec 21	-108	35	71
30 Sep 21	-100	31	66
30 Jun 21	-91	27	60
31 Mar 21	-81	24	54
31 Dec 20	-75	23	48
30 Sep 20	-70	21	46
30 Jun 20	-61	20	40
31 Mar 20	-53	17	36
31 Dec 19	-43	15	30
30 Sep 19	-35	12	25
30 Jun 19	-30	10	23
31 Mar 19	-31	9	20
31 Dec 18	-31	9	19
30 Sep 18	-28	8	15
30 Jun 18	-26	7	13
31 Mar 18	-20	6	11
31 Dec 17	-17	4	9

Guadagni di qualità: 7R8 al momento non è redditizia.

Margine di profitto in crescita: 7R8 al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: 7R8 non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 31.4% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di 7R8 nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: 7R8 non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( -18.2% ).

Rendimento del capitale proprio

ROE elevato: 7R8 ha un Return on Equity negativo ( -55.84% ), in quanto al momento non è redditizio.

Replimune Group Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate